

**PROJECT TITLE****Translation of an early prostate cancer tissue signature in urine liquid biopsy for prognosis and active surveillance****PRINCIPAL INVESTIGATOR**

Dr. Jane Bayani – Ontario Institute for Cancer Research

**SCIENTIFIC SUMMARY**

Active surveillance in prostate cancer requires multiple invasive biopsies which can have serious side effects, yet this surveillance is only helpful in about 10 percent of cases. Nevertheless, it continues to be required because there is not a better option. To address the need for improve testing at diagnosis, Dr. Bayani’s team will use a molecular test called “PRONTO” for use in tissue biopsy specimens, which was developed through a collaborative multi-institutional program led by OICR (Adaptive Oncology) researchers including Dr. Bayani. This new study will adapt the PRONTO signatures for use in urine by testing matched biopsies and urine from men with early prostate cancer. Validation in this cohort will provide the necessary level of evidence to integrate non-invasive urine profiling at the time of diagnosis with targeted MRI biopsy and tissue risk profiling, through active surveillance using sequential urine samples as a practice-changing clinical management strategy for early prostate cancer